Nicole L Kallewaard
Overview
Explore the profile of Nicole L Kallewaard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
2970
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Upadhyaya H, Chien J, Long A, Bohm M, Kallewaard N, Macpherson L, et al.
Infect Dis Ther
. 2023 Jun;
12(7):1861-1873.
PMID: 37329415
Introduction: Bamlanivimab and etesevimab (BAM + ETE) are monoclonal antibodies (mAbs) effective in reducing COVID-19-related hospitalizations and all-cause mortality in adult participants at increased risk for severe disease. We present...
2.
Dippel A, Gallegos A, Aleti V, Barnes A, Chen X, Christian E, et al.
MAbs
. 2022 Dec;
15(1):2152526.
PMID: 36476037
To combat the COVID-19 pandemic, potential therapies have been developed and moved into clinical trials at an unprecedented pace. Some of the most promising therapies are neutralizing antibodies against SARS-CoV-2....
3.
Benschop R, Tuttle J, Zhang L, Poorbaugh J, Kallewaard N, Vaillancourt P, et al.
Sci Transl Med
. 2022 Jun;
14(655):eabn3041.
PMID: 35679357
As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of severe acute respiratory syndrome coronavirus...
4.
Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al.
Cell Rep
. 2022 May;
39(7):110812.
PMID: 35568025
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs)...
5.
Loo Y, McTamney P, Arends R, Abram M, Aksyuk A, Diallo S, et al.
Sci Transl Med
. 2022 Jan;
14(635):eabl8124.
PMID: 35076282
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, there remains a need for more prevention and treatment options for individuals remaining at risk of coronavirus disease...
6.
Zhang L, Poorbaugh J, Dougan M, Chen P, Gottlieb R, Huhn G, et al.
Front Immunol
. 2021 Dec;
12:790469.
PMID: 34956222
Background: Neutralizing monoclonal antibodies (mAbs) to SARS-CoV-2 are clinically efficacious when administered early, decreasing hospitalization and mortality in patients with mild or moderate COVID-19. We investigated the effects of receiving...
7.
Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb R, Chen P, et al.
N Engl J Med
. 2021 Jul;
385(15):1382-1392.
PMID: 34260849
Background: Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and...
8.
Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al.
bioRxiv
. 2021 May;
PMID: 33972947
In Brief: LY-CoV1404 is a potent SARS-CoV-2-binding antibody that neutralizes all known variants of concern and whose epitope is rarely mutated. Highlights: LY-CoV1404 potently neutralizes SARS-CoV-2 authentic virus and known...
9.
Gottlieb R, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al.
JAMA
. 2021 Jan;
325(7):632-644.
PMID: 33475701
Importance: Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19. Objective: To determine the effect of bamlanivimab monotherapy and combination therapy with...
10.
Zost S, Gilchuk P, Case J, Binshtein E, Chen R, Nkolola J, et al.
Nature
. 2020 Jul;
584(7821):443-449.
PMID: 32668443
The ongoing pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health and the medical countermeasures...